Quality Level
biological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
2C8, monoclonal
mol wt
36 kDa
species reactivity
human
technique(s)
direct ELISA: 1:10,000, flow cytometry: 1:200-1:400, immunohistochemistry: 1:200-1:1,000, indirect immunofluorescence: 1:200-1:1,000, western blot: 1:500-1:2,000
isotype
IgG2b
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... PBK(55872)
Immunogen
Purified recombinant fragment of human PBK expressed in E.coli.
Mouse monoclonal antibody raised against PBK
Mouse monoclonal antibody raised against PBK
Physical form
Ascitic fluid containing 0.03% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
存储类别
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Giacomo Pirovano et al.
Molecular imaging and biology, 21(4), 705-712 (2018-10-26)
Lymphokine-activated killer T cell-originated protein kinase (TOPK) is a fairly new cancer biomarker with great potential for clinical applications. The labeling of a TOPK inhibitor with F-18 can be exploited for positron emission tomography (PET) imaging allowing more accurate patient
Giacomo Pirovano et al.
European journal of nuclear medicine and molecular imaging, 47(4), 1003-1010 (2019-11-18)
OTS514 is a highly specific inhibitor targeting lymphokine-activated killer T cell-originated protein kinase (TOPK). A fluorescently labeled TOPK inhibitor could be used for tumor delineation or intraoperative imaging, potentially improving patient care. Fluorescently labeled OTS514 was obtained by conjugating the
Giacomo Pirovano et al.
British journal of cancer, 117(4), 503-512 (2017-07-06)
Tumour-specific radiosensitising treatments may enhance the efficacy of radiotherapy without exacerbating side effects. In this study we determined the radiation response following depletion or inhibition of TOPK, a mitogen-activated protein kinase kinase family Ser/Thr protein kinase that is upregulated in
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SAB5300406-100UL | 04061837600784 |